As preferred development and manufacturing partner, Catalent will be able to offer its partners access to the TFF technology
TFF Pharmaceuticals and Catalent have announced a collaboration agreement focused on the generation, testing and manufacture of dry powder formulations for a range of biotherapeutics through the application of TFF’s Thin Film Freezing technology.
Under the agreement, Catalent will provide its scale-up expertise and manufacturing capabilities as preferred development and manufacturing partner, and be able to offer its customers access to the TFF technology, which the companies say has the potential to increase the adoption of the pulmonary route for the systemic delivery of biotherapeutics.
“Catalent is widely known as a global leader in enabling pharmaceutical development and manufacturing and has distinguished itself by demonstrating cutting-edge expertise across multiple modalities and innovative projects. We are therefore delighted to significantly expand our collaboration with the Catalent team,” said Glenn Mattes, CEO of TFF Pharmaceuticals. “This strategic collaboration significantly expands our access to manufacturing capabilities and provides scalability for our technology, while simultaneously affording us the opportunity to build our portfolio of technology licensing partnerships.”
Jonathan Arnold, President, Oral and Specialty Delivery at Catalent said: “Catalent is pleased to leverage its extensive expertise in the development and CGMP manufacture of dry powders in order to potentially bring TFF Pharmaceuticals’ unique and differentiated technology to scale.”